Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Stamceltransplantatie versus bestraling bij primair czs-lymfoom
dec 2022 | Lymfoom, Neuro-oncologie, Radiotherapie, Stamceltransplantatie